Adler Institute for Advanced Imaging

FOR REFERRING PHYSICIANS

Referring A Patient

The basic information we need from you when referring a patient.


The Clinical Value of PET/CT

How PET/CT works and why it so valuable in improving patient outcomes.


Using PET/CT

Use of PET/CT in Oncology, Cardiology, and Neurology


Forms

Necessary forms for your patient's scan.




ACR Accreditation Logo
REFERRING PHYSICIANSUsing PET and PET/CT

Use of PET in Cardiology

PET imaging can play an important role in the accurate assessment of myocardial perfusion, free from attenuation artifacts. PET is also the gold standard for determining myocardial viability and suitability for coronary intervention.

Using PET to Assess Myocardial Viability

Positron Emission Tomography (PET), utilizing 18-fluorodeoxyglucose (FDG), is a well-recognized method to assess myocardial viability. FDG uptake equates with viability, and as many as 30%-50% of regions felt to be scar by standard nuclear tests are found to be viable with PET. Additionally, categorization of myocardium as viable versus non-viable has important prognostic implications. The identification of viability on the PET scan recommends revascularization, resulting in functional as well as symptomatic improvement in many patients.

Using PET for Myocardial Perfusion Imaging

Positron Emission Tomography (PET) myocardial perfusion imaging can be performed with either N-13 ammonia (cyclotron-produced) or rubidium-82 (generator-produced). Advantages of PET versus SPECT include higher spatial resolution, better attenuation correction, quantitation, true stress function analysis, reduced radiation, and higher accuracy. Good candidates for PET include: patients with suboptimal SPECT or SPECT results at odds with the clinical data, obese patients, large breasted women, and diabetics. Presently, PET perfusion studies are best performed with pharmacologic stress (e.g., adenosine, dipyridamole, or dobutamine), and can be completed on modern PET/CT systems in less than 30 minutes.